For health care professionals in EUROPE excepted those practicing in France as the following pages are intended to all International health care professionals and are not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011 article 34. Other health care professionals should select their country in the top right corner of the  website.

Please note that the following pages are exclusively reserved for health care professionals in countries with applicable health authority product registrations. To the extent this site contains information, reference guides and databases intended for use by licensed medical professionals, such materials are not intended to offer professional medical advice. Prior to use, please consult device labeling for prescriptive information and operating instructions.

This Website is protected by the laws on copyright and by the relevant international conventions. It is strictly forbidden to make copies, whether partial or total and on whichever media without prior approval.

Eluvia banner image


EMINENT randomised controlled trial results

Eminent Clinical Trial Results

EMINENT3 is the largest randomised Controlled Trial (2:1) comparing Eluvia™ Drug-Eluting Vascular Stent System to self-expanding bare metal stents (BMS) for SFA/PPA; EU multi-center; superiority trial; core lab adjudicated.

EMINENT RCT 1-year primary patency results

Eluvia demonstrated superiority over BMS1 with a statistically significant primary patency of 85.4% versus 76.3% through 1-Year.

1-Year Primary Kaplen Meijer Patency estimate

Eluvia demonstrated a statistically significant greater rate of sustained clinical improvement without reintervention over BMS through 1-Year.6

EMINENT RCT 1-year primary sustained clinical improvement

EMINENT Trial Eluvia 1 Year Primary Sustained

EMINENT randomised controlled trial details

  Eluvia DES
All Death, Major Amputation, TLR 11.8% (56/474) 11.8% (31/263) 0.9912
All-Cause Death at 1-Year 2.7% (13/474) 1.1% (3/263) 0.1528
Target Limb Major Amputation 0.2% (1/474) 0.0% (0/263) 1.0000
Clinically-Driven Target Lesion Revascularization 8.4% (40/474) 10.6% (28/263) 0.3212
  Eluvia DES
Age (Years) 68.9 ± 8.7  68.9 ± 9.1 0.9739
Male Gender 71.5% 67.4% 0.2431
Diabetes Mellitus (medically-treated) 31.9% 32.6% 0.8440
History of Smoking (current/previous) 36.0% / 39.6% 36.0% / 41.6% 0.9849 / 0.5884
Percent Stenosis (%) 86.6 ± 15.2 85.5 ± 15.3 0.3629
Total Occlusions 42.3% 39.9% 0.5372
Total Stented Length (mm) 105.8 ± 48.4 109.2 ± 49.8 0.3858
Target Lesion Length (mm) 75.6 ± 50.3 72.2 ± 47.0 0.3815
Moderately Calcified 21.6% 26.0% 0.1849
Severely Calcified 30.3% 31.1% 0.8122

Ordering and reimbursement

Get downloads for ordering information and reimbursement coding guides for our drug-eluting technologies.

Stay up to date

Receive emails about the latest drug-eluting technology news, innovations and events in your area.

1. EMINENT Trial: A global randomized controlled multi-center trial with 2:1 randomization of the Eluvia™ Drug-Eluting Stent against commercially-available Self-Expanding Bare Nitinol Stents, single-blind, superiority design; independent core lab adjudication. Primary Endpoint: 1-Year Binary Primary Patency rate of 83.2% in the Eluvia arm vs. 74.3% in the Bare-Metal Stenting arm (p-value = 0.0077).

3. EMINENT RCT 1-Year results presented by Yann Gouëffic, MD. VIVA 2021

4. Kaplan-Meier Estimate: Primary patency defined as core-lab assessed duplex ultrasound peak systolic velocity ratio (PSVR) ≤ 2.4 at 1-year in the absence of clinically-driven TLR or bypass of the target lesion.

5. Log-rank p-value compares the entire K-M curves from time point zero to day 395 (full 1-year follow-up window)

6. In EMINENT, primary sustained clinical improvement was defined as an improvement (decrease) by at least 1 Rutherford category, without TLR.

The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.